[Form 4] Arteris, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Insider sale reported by Arteris VP & CFO Nicholas B. Hawkins on Form 4.

• Transaction date: 08/01/2025.
• Shares sold: 5,638 common shares (reported as Direct disposition).
• Weighted-average sale price: $9.0328; reported range: $9.00 to $9.27.
• Sale executed pursuant to a 10b5-1 trading plan adopted May 20, 2024.
• Shares beneficially owned after the transaction: 119,272 (Direct).
• Form signed by attorney-in-fact Paul Alpern on 08/04/2025.

Positive

• Transaction executed under a pre-established 10b5-1 trading plan adopted May 20, 2024
• Filing discloses weighted-average price and offers to provide per-price execution details, enhancing transparency

Negative

• None.

Insights

Financial Analyst

TL;DR: Routine, preplanned insider sale under a 10b5-1 plan; modest share quantity at ~$9.03 average.

The filing discloses a direct disposition of 5,638 Arteris (AIP) shares by VP/CFO Nicholas B. Hawkins on 08/01/2025 at a weighted-average price of $9.0328. The sale was executed under a 10b5-1 plan adopted 05/20/2024, which indicates a pre-established trading arrangement rather than an opportunistic trade. Beneficial ownership after the sale is reported as 119,272 shares. From a financial-analysis perspective, the disclosure is transparent but does not, by itself, provide material new information about company operations or guidance.

Corporate Governance Expert

TL;DR: Governance disclosure consistent with compliance norms; use of attorney-in-fact and 10b5-1 plan documented.

The Form 4 documents a compliance-focused insider transaction: the sale occurred pursuant to a documented 10b5-1 trading plan and the filer authorized an attorney-in-fact to sign the filing on 08/04/2025. The filer also offers to provide detailed per-price execution data on request, which supports transparency. The filing contains no indication of undisclosed arrangements or derivative activity. This is a routine governance disclosure with neutral investor implications based on the information provided.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hawkins Nicholas B.

(Last) (First) (Middle)

C/O ARTERIS, INC.

900 E. HAMILTON AVE., SUITE 300

(Street)

CAMPBELL CA 95008

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Arteris, Inc. [ AIP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	VP and Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/01/2025		S(1)		5,638	D	$9.0328(2)	119,272	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Transaction made pursuant to a 10b5-1 trading plan that was adopted by the Reporting Person on May 20, 2024.

2. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $9.00 to $9.27 inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

	/s/ Paul Alpern, as Attorney-in-Fact for Hawkins Nicholas B.	08/04/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Nicholas B. Hawkins report on the Form 4 for Arteris (AIP)?

He reported a direct sale of 5,638 common shares on 08/01/2025, executed under a 10b5-1 plan, with 119,272 shares owned after the sale.

When was the 10b5-1 trading plan adopted for the reported sale (AIP)?

The 10b5-1 trading plan was adopted on May 20, 2024, per the Form 4 explanation.

At what price were the AIP shares sold according to the Form 4?

The weighted-average sale price was reported as $9.0328; individual trades occurred in the range $9.00 to $9.27.

Who signed the Form 4 for Nicholas B. Hawkins (AIP)?

The Form 4 was signed by Paul Alpern, as Attorney-in-Fact for Hawkins, dated 08/04/2025.

What is Hawkins' relationship to Arteris (AIP)?

The filing lists Nicholas B. Hawkins as an Officer with the title VP and Chief Financial Officer.